Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

BACKGROUND: Activation of the MET oncogene promotes tumor growth, invasion and metastasis in several tumor types. Additionally, MET is activated as a compensatory pathway in the presence of EGFR blockade, thus resulting in a mechanism of resistance to EGFR inhibitors. METHODS: We have investigated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Madoz-Gúrpide, Juan, Zazo, Sandra, Chamizo, Cristina, Casado, Victoria, Caramés, Cristina, Gavín, Eduardo, Cristóbal, Ion, García-Foncillas, Jesús, Rojo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552997/
https://www.ncbi.nlm.nih.gov/pubmed/26319934
http://dx.doi.org/10.1186/s12967-015-0633-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552997/
https://www.ncbi.nlm.nih.gov/pubmed/26319934
http://dx.doi.org/10.1186/s12967-015-0633-7

Ejemplares similares